Keywords: ALT; Acute hepatitis B; Adolescents; Breastfeeding; CHB; Children; Chronic hepatitis B; FDA; Food and Drug Administration; Guidelines; HBIG; HBV; HCC; Hepatitis B virus; IFN; Immunosuppressed; Management; NA; PegINF; Pregnancy; Resistance; SVR; Transplantation; Treatment; ULN; VR; WHO; World Health Organization; alanine aminotransferases; cccDNA; chronic hepatitis B; covalently closed circular DNA; hepatitis B immunoglobulins; hepatitis B virus; hepatocellular carcinoma; interferon; nucleos(t)ide analogues; pegylated interferon; sustained virological response; upper limit of normal; virologic response.